Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of Localised Pancreatic Adenocarcinoma Following Preoperative (m)FOLFIRINOX By Ogkologos - March 11, 2025 746 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients... March 17, 2025 Vaping Pods Produce High Nicotine Levels in Young Users October 5, 2018 Talking With Your Doctor About Negative Emotions During Cancer November 3, 2020 Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases August 26, 2019 Load more HOT NEWS Dogs Can Sniff Out COVID-19 After Just One Week Of Training,... Why the Bone Marrow Registry Needs More Diverse Donors and How... Magnetic Fish-Shaped Microbots Deliver Chemotherapy to Exactly Where It’s Needed Navigating the Challenges of Gynecologic Cancer Survivorship: An Expert Perspective
